Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Loss and Comprehensive Loss

v3.21.2
Consolidated Statements of Loss and Comprehensive Loss - CAD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Details    
Sales [1] $ 23,338,528 $ 0
Cost of sales, before fair value adjustments 9,486,087 0
Net Sales 13,852,441 0
Unrealized change in fair value of biological assets [2] (543,116) 0
Realized fair value amounts included in inventory sold 45,232 0
Gross profit 13,354,557  
Expenses    
General and administration 10,695,379 2,951,403
Salaries and wages 6,777,330 568,167
Depreciation and amortization [3] 15,291,977 1,898
Earn-out compensation [4] 9,805,500 0
Share-based compensation [5] 3,955,976 3,796,095
Sales and marketing 1,762,223 913,412
Total Expenses 48,288,385 8,230,975
Loss from operations before other expenses (income) (34,933,828) (8,230,975)
Other expense (income)    
Finance expense (income), net 5,272,428 (399,060)
Foreign exchange 1,677,976 1,385,803
Management fees (425,610) (1,111,637)
(Gain) Loss on revaluation of call/put option [6] (53,619,465) 4,407,819
Gain on disposal of property, plant and equipment [7] (232,874) 0
Write off of deposit [4] 1,853,059 0
Listing expense [8] 31,705,481 0
Revaluation of financial instruments 530,451 0
Total other expense (income) (13,238,554) 4,282,925
Loss before income taxes (21,695,274) (12,513,900)
Current income tax expense [9] 3,125,261 0
Deferred income tax recovery [9] (6,243,668) 0
Net loss (18,576,867) (12,513,900)
Translation adjustment on consolidation of foreign subsidiaries (1,896,622) 0
Comprehensive loss $ (20,473,489) $ (12,513,900)
Net loss per share, basic and diluted [10] $ (0.14) $ (0.16)
Weighted average number of shares outstanding 137,571,316 80,700,135
[1] Note 25.
[2] Note 8.
[3] Notes 10, 13.
[4] Note 6.
[5] Note 18.
[6] Note 12.
[7] Note 10.
[8] Note 5.
[9] Note 20.
[10] Note 19.